Skip to main content
. 2016 Jun;16(2):145–151.

Figure 3.

Figure 3

Changes in the expression of Runx2, Osterix, osteocalcin and RANKL in OVX mice by treatment with TRPV1, ASIC3, and P2X2/3 antagonists. The Runx2 (A, B) and Osterix (A, C) expression was completely inhibited by treatment with TRPV1 (+anti-TRPV1, n=3), ASIC3 (+anti-ASIC3, n=3) or P2X2/3 (+anti-P2X2/3, n=3) antagonists. The osteocalcin expression was significantly inhibited by treatment with TRPV1 (+anti-TRPV1), ASIC3 (+anti-ASIC3) or P2X2/3 (+anti-P2X2/3) antagonists (A, D). The up-regulation of RANKL expression was completely inhibited by treatment with TRPV1 (+anti-TRPV1) and ASIC3 (+anti-ASIC3) antagonists, although no inhibitory effect was observed for the P2X2/3 antagonist (A, E). Expression levels are shown as the ratio of the gene of interest to the control gene (GAPDH). *P<0.01, **P<0.05. The RT-PCR picture (A) demonstrated a representative data and the error bars (B, C, D, E) meant variation of the samples from different mice in independent femurs.